Haesook Teresa Kim

Phenotypic and functional characterization of the CD6-ALCAM T cell costimulatory pathway after allogeneic cell transplantation.

Rambaldi B, Kim HT, Arihara Y, Asano T, Reynolds C, Manter M, Halpern M, Weber A, Koreth J, Cutler C, Gooptu M, Nikiforow S, Ho VT, Antin JH, Romee R, Ampudia J, Ng C, Connelly S, Soiffer RJ, Ritz J.

Haematologica. 2022 Apr 28. PMID: 35484649

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.

Whangbo J, Nikiforow S, Kim HT, Wahl J, Reynolds CG, Chamling Rai S, Kim S, Burden AT, Alho A, Lacerda JF, Alyea EP, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Ritz J, Koreth J.

Blood Adv. 2022 Apr 27. PMID: 35475885

Favorable Outcomes Following Allogeneic Transplantation in Adults with Hemophagocytic Lymphohistiocytosis.

Gooptu M, Kim HT, Jacobsen ED, Fisher DC, LaCasce AS, Ho VT, Cutler CS, Koreth J, Soiffer RJ, Antin JH, Berliner N, Nikiforow S.

Blood Adv. 2022 Apr 19. PMID: 35439287

GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial.

Ho VT, Kim HT, Brock J, Galinsky I, Daley H, Reynolds C, Weber A, Pozdnyakova O, Severgnini M, Nikiforow S, Cutler C, Koreth J, Alyea EP, Antin JH, Gooptu M, Romee R, Shapiro R, Chen YB, Rosenblatt J, Avigan D, Hodi FS, Dranoff G, Wu CJ, Ritz J, Soiffer RJ.

Blood Adv. 2022 Apr 12. 6(7):2183-2194. PMID: 34807983

Expansion, persistence, and efficacy of donor memory-like NK cells infused for post-transplant relapse.

Shapiro RM, Birch GC, Hu G, Vergara Cadavid J, Nikiforow S, Baginska J, Ali AK, Tarannum M, Sheffer M, Abdulhamid YZ, Rambaldi B, Arihara Y, Reynolds C, Halpern MS, Rodig SJ, Cullen N, Wolff JO, Pfaff KL, Lane AA, Lindsley RC, Cutler CS, Antin JH, Ho VT, Koreth J, Gooptu M, Kim HT, Malmberg KJ, Wu CJ, Chen J, Soiffer RJ, Ritz J, Romee R.

J Clin Invest. 2022 Mar 29. PMID: 35349491

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older AML patients.

Murdock HM, Kim HT, Denlinger N, Vachhani P, Hambley BC, Manning BS, Gier S, Cho C, Tsai HK, McCurdy SR, Ho VT, Koreth J, Soiffer RJ, Ritz J, Carroll MP, Vasu S, Perales MA, Wang ES, Gondek LP, Devine SM, Alyea EP, Lindsley RC, Gibson CJ.

Blood. 2022 Mar 14. PMID: 35286378

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant.

Nauffal M, Kim HT, Richardson PG, Soiffer RJ, Antin JH, Cutler C, Nikiforow S, Gooptu M, Koreth J, Romee R, Ho VT.

Blood Adv. 2022 01 11. 6(1):181-188. PMID: 34666352

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active.

Garcia JS, Kim HT, Murdock HM, Cutler CS, Brock J, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, Loschi F, Ryan J, Fell G, Karp HQ, Lucas F, Kim AS, Potter D, Mashaka T, Stone RM, DeAngelo DJ, Letai A, Lindsley RC, Soiffer RJ, Antin JH.

Blood Adv. 2021 12 28. 5(24):5536-5545. PMID: 34614506

Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution.

Maurer K, Kim HT, Kuczmarski TM, Garrity HM, Weber A, Reynolds CG, Liney D, Cutler C, Antin JH, Koreth J, Ritz J, Shapiro RM, Romee R, Wu CJ, Soiffer RJ, Nikiforow S, Ho VT, Gooptu M.

Blood Adv. 2021 12 14. 5(23):5140-5149. PMID: 34581754

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation.

Kim HT, Baker PO, Parry E, Davids M, Alyea EP, Ho VT, Cutler C, Koreth J, Gooptu M, Romee R, Nikiforow S, Antin JH, Ritz J, Soiffer RJ, Wu CJ, Brown JR.

Haematologica. 2021 12 01. 106(12):3219-3222. PMID: 34435483